Cochrane review of long-acting muscarinic antagonist (LAMA) plus long-acting beta-agonist (LABA) versus LABA plus inhaled corticosteroid (ICS) for stable chronic obstructive pulmonary disease (COPD)
Posted on:
In a Cochrane review of 11 studies, which included 9839 participants with stable chronic COPD, LAMA+LABA treatment had fewer exacerbations, a larger improvement of FEV1, a lower risk of pneumonia, and more frequent improvement in quality of life as measured by an increase over 4 units or more of the St. George’s Respiratory Questionnaire (SGRQ) compared with LABA+ICS treatment. The findings support the recently updated GOLD guidance.